Andrea K Finlay1, Alex H S Harris2, Joel Rosenthal3, Jessica Blue-Howells4, Sean Clark5, Jim McGuire6, Christine Timko7, Susan M Frayne8, David Smelson9, Elizabeth Oliva10, Ingrid Binswanger11. 1. Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Andrea.Finlay@va.gov. 2. Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Alexander.Harris2@va.gov. 3. Veterans Justice Programs, Department of Veterans Affairs, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Joel.Rosenthal@va.gov. 4. Veterans Justice Programs, Department of Veterans Affairs, Greater Los Angeles Health Care System, 11301 Wilshire Blvd., Los Angeles, CA 90073, USA. Electronic address: Jessica.Blue-Howells@va.gov. 5. Veterans Justice Programs, Department of Veterans Affairs, 2250 Leestown Road, Lexington, KY 40511, USA. Electronic address: Sean.Clark2@va.gov. 6. Veterans Justice Programs, Department of Veterans Affairs, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: jimfmcguire@yahoo.com. 7. Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA. Electronic address: ctimko@stanford.edu. 8. Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA; Women's Health Service, Medical Service, VA Palo Alto Health Care System, 3801 Miranda Ave., Palo Alto, CA 94304, USA; Division of General Medical Disciplines, Stanford University School of Medicine, 1265 Welch Road, Stanford, CA 94305, USA. Electronic address: Susan.Frayne@va.gov. 9. National Center on Homelessness Among Veterans, Edith Nourse Rogers Memorial Veterans Hospital, 200 Springs Road, Bedford, MA 01730, USA; Department of Psychiatry, University of Massachusetts Medical School, 55 N. Lake Ave., Worcester, MA 01655, USA. Electronic address: David.Smelson@umassmed.edu. 10. Program Evaluation Resource Center, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Andrea.Finlay@va.gov. 11. Kaiser Permanente Institute for Health Research, 10065 E Harvard Ave., Suite 300, Denver, CO 80231, USA; Division of General Internal Medicine, University of Colorado School of Medicine, 12631 E. 17th Ave., Aurora, CO 80204, USA. Electronic address: Andrea.Finlay@va.gov.
Abstract
BACKGROUND: Pharmacotherapy - methadone, buprenorphine, or naltrexone - is an evidence-based treatment for opioid use disorder, but little is known about receipt of these medications among veterans involved in the justice system. The current study examines receipt of pharmacotherapy for opioid use disorder among veterans with a history of justice involvement at U.S. Veterans Health Administration (VHA) facilities compared to veterans with no justice involvement. METHODS: Using national VHA clinical and pharmacy records, we conducted a retrospective cohort study of veterans with an opioid use disorder diagnosis in fiscal year 2012. Using a mixed-effects logistic regression model, we examined receipt of pharmacotherapy in the 1-year period following diagnosis as a function of justice involvement, adjusting for patient and facility characteristics. RESULTS: The 1-year rate of receipt for pharmacotherapy for opioid use disorder was 27% for prison-involved veterans, 34% for jail/court-involved veterans, and 33% for veterans not justice-involved. Compared to veterans not justice-involved, those prison-involved had 0.75 lower adjusted odds (95% confidence interval [CI]: 0.65-0.87) of receiving pharmacotherapy whereas jail/court-involved veterans did not have significantly different adjusted odds. CONCLUSIONS: Targeted efforts to improve receipt of pharmacotherapy for opioid use disorder among veterans exiting prison is needed as they have lower odds of receiving these medications. Published by Elsevier Ireland Ltd.
BACKGROUND: Pharmacotherapy - methadone, buprenorphine, or naltrexone - is an evidence-based treatment for opioid use disorder, but little is known about receipt of these medications among veterans involved in the justice system. The current study examines receipt of pharmacotherapy for opioid use disorder among veterans with a history of justice involvement at U.S. Veterans Health Administration (VHA) facilities compared to veterans with no justice involvement. METHODS: Using national VHA clinical and pharmacy records, we conducted a retrospective cohort study of veterans with an opioid use disorder diagnosis in fiscal year 2012. Using a mixed-effects logistic regression model, we examined receipt of pharmacotherapy in the 1-year period following diagnosis as a function of justice involvement, adjusting for patient and facility characteristics. RESULTS: The 1-year rate of receipt for pharmacotherapy for opioid use disorder was 27% for prison-involved veterans, 34% for jail/court-involved veterans, and 33% for veterans not justice-involved. Compared to veterans not justice-involved, those prison-involved had 0.75 lower adjusted odds (95% confidence interval [CI]: 0.65-0.87) of receiving pharmacotherapy whereas jail/court-involved veterans did not have significantly different adjusted odds. CONCLUSIONS: Targeted efforts to improve receipt of pharmacotherapy for opioid use disorder among veterans exiting prison is needed as they have lower odds of receiving these medications. Published by Elsevier Ireland Ltd.
Entities:
Keywords:
Buprenorphine; Criminal Justice; Methadone; Opioid-related disorders; United States Department of Veterans Affairs
Authors: Jack Tsai; Robert A Rosenheck; Wesley J Kasprow; James F McGuire Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2013-03-19 Impact factor: 4.328
Authors: Jan Gryczynski; Timothy W Kinlock; Sharon M Kelly; Kevin E O'Grady; Michael S Gordon; Robert P Schwartz Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Donna M Coviello; James W Cornish; Kevin G Lynch; Tamara Y Boney; Cynthia A Clark; Joshua D Lee; Peter D Friedmann; Edward V Nunes; Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Elie S Nuwayser; Charles P O'Brien Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Ingrid A Binswanger; Carolyn Nowels; Karen F Corsi; Jason Glanz; Jeremy Long; Robert E Booth; John F Steiner Journal: Addict Sci Clin Pract Date: 2012-03-15
Authors: Andrea K Finlay; Jessie J Wong; Laura S Ellerbe; Anna Rubinsky; Shalini Gupta; Thomas R Bowe; Eric M Schmidt; Christine Timko; Jennifer L Burden; Alex H S Harris Journal: J Stud Alcohol Drugs Date: 2018-11 Impact factor: 2.582
Authors: Jessica J Wyse; Adam J Gordon; Steven K Dobscha; Benjamin J Morasco; Elizabeth Tiffany; Karen Drexler; Friedhelm Sandbrink; Travis I Lovejoy Journal: Subst Abus Date: 2018 Impact factor: 3.716
Authors: Ryan D McDonald; Babak Tofighi; Eugene Laska; Keith Goldfeld; Wanda Bonilla; Mara Flannery; Nadina Santana-Correa; Christopher W Johnson; Neil Leibowitz; John Rotrosen; Marc N Gourevitch; Joshua D Lee Journal: Contemp Clin Trials Date: 2016-05-10 Impact factor: 2.226
Authors: Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger Journal: J Gen Intern Med Date: 2020-06-24 Impact factor: 5.128
Authors: Andrea K Finlay; Alex H S Harris; Joel Rosenthal; Jessica Blue-Howells; Sean Clark; Bessie Flatley; Christine Timko Journal: Rural Ment Health Date: 2018-01
Authors: Andrea K Finlay; Ingrid A Binswanger; Christine Timko; David Smelson; Matthew A Stimmel; Mengfei Yu; Tom Bowe; Alex H S Harris Journal: J Subst Abuse Treat Date: 2018-10-02